Cell Therapies – Special Topics – Special Topics: CAR T-Cell Therapy Forecast – Multi-indication

The accelerated approvals of Kymriah (Novartis) for the treatment of children oryoung adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite Pharma, a Gilead company) for relapsed/refractory large B-cell lymphoma herald a new era in cancer immunotherapy. In this report, we present a comprehensive market forecast for the current and emerging chimeric antigen receptor (CAR) T-cell therapies across oncology indications. We also provide key opinion leaders’(KOLs’) insights regarding the current and emerging CAR T-cell treatment landscape.


  • What is the commercial potential of CAR T-cell therapies by brand, indication, and geography?
  • How will the CAR T-cell market evolve over the 2017-2027 forecast period?
  • What are the ongoing clinical trials of currently approved CAR T-cell therapies? Which additional indications and settings do we expect Kymriah and Yescarta to secure?
  • Which emerging CAR T-cell therapies do we anticipate will gain approval, and will they be commercially successful?
  • What are the strengths and weaknesses of each brand, and what are KOLs’ opinions of each therapy?
  • What challenges could limit the adoption of autologous CD19-targeted CAR T-cell therapies? What are the competitive threats and pressures thatCAR T-celltherapiesareexpected to face in the oncology landscape?
  • What are the opinions of expert oncologists on the future CAR T-cell therapy landscape?

United States, EU5, Japan

14 country-specific interviews with thought-leading hematologist-oncologists and trial investigators.

Drug-treated patient populations for acute lymphoblastic leukemia, relevant non-Hodgkin’s lymphoma subpopulations, chronic lymphocytic leukemia, and multiple myeloma, by country and line of therapy.

Ten-year, annualized, drug-level sales and patient shares for CAR T-cell therapies through 2027, segmented by indication and patient subpopulation.

The CAR T-Cell Therapy Special Topics Report is a unique product offering a consolidated full market forecast of the CAR T-cell landscape in oncology through 2027. This forecast is supplemented with interviews conducted with KOLs from all seven major pharmaceutical markets under study.